65,437 trials
Fecal Incontinence
Primary: Fecal Incontinence Incidence From Baseline (Pre-treatment) Through 24 Months Post-treatment — 6.9; 3.0; 3.7; 3.7 Number of FI episodes/14 day period
Supraventricular Tachycardia
Primary: Incidence of Recurrent Supraventricular Tachycardia (SVT) Requiring Medical Intervention to Terminate the Episode. — 12; 18 percentage of participants
Coughing
Primary: Coughing Grade — 0.6; 1.4 units on a scale
Esophageal Cancer
Primary: Complete Pathologic Response — 12 participants
Catheter-related Bloodstream Infection
Primary: The Number of Catheter Related Bloodstream Infections (BSI) /1000 Catheter Days in Both Arms — 4.74; 4.72 BSIs /1000 catheter days — p=0.05
Urinary Bladder Neoplasms
Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants
Healthy
Primary: Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞) — 281.05; 485.48; 410.46 ng*h/mL
Aphakia · Cataract
Primary: Visual Acuity — 108 Participants
Severe Sepsis
Primary: Change From Baseline in Creatinine Values — -78.6; -196.8; -25.1; -10.9 μmol/L
Parkinson's Disease With Dementia
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks. — 71.6; 66.7; 67.9; 65.2 Scores on a scale
Leukemia · Lymphoma
Primary: Participants With Objective Response — 0; 1; 13 Participants
Diabetes Mellitus, Type 2 · Newly Diagnosed
Primary: the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 Weeks — -1.8; -1.74; -1.47 percentage of HbA1c — p=<0.05
Alcohol Abuse · Cocaine Abuse · Marijuana Abuse
Primary: Percentage of Days Used Drugs or Alcohol — 18; 21; 6; 7 percentage of days — p=0.88
Cesarean Delivery · Wound Infection · Obesity
Primary: Cefazolin Levels — 18.36; 40.11; 21.73; 34.89 mcg/mL — p=<0.01
Breast Cancer
Primary: Median Time to Progression — 149 Days